Department of Surgery, Division of Clinical Medical Science, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
World J Surg. 2010 Aug;34(8):1900-7. doi: 10.1007/s00268-010-0577-2.
The aim of the present study was to clarify the prognostic impact of para-aortic lymph node metastasis in pancreatic ductal adenocarcinoma.
Medical records of 103 consecutive patients with pancreatic ductal adenocarcinoma, who underwent pancreatic resection with regional and para-aortic lymph node dissection were reviewed retrospectively. Clinicopathological factors and survival were compared between patients with and without para-aortic lymph node metastasis.
Tumor size (p = 0.045), extrapancreatic nerve plexus invasion (p = 0.043), UICC pT factor (p = 0.026), and surgical margin status (p = 0.002) were associated significantly with para-aortic lymph node metastasis. Postoperative adjuvant chemotherapy (p < 0.001) and absence of extrapancreatic nerve plexus invasion (p = 0.041) were associated independently with longer survival, but para-aortic lymph node metastasis (p = 0.078) was not associated significantly with survival by multivariate analysis. The 2- and 5-year survival rates and median survival time of patients with and without para-aortic lymph node metastasis were 12, 0%, 12.4 months and 49, 23%, 14.5 months, respectively, and there was a significant difference in survival between the two groups by a log-rank test (p < 0.001). Postoperative adjuvant chemotherapy significantly improved the survival of patients with para-aortic lymph node metastasis (p = 0.025).
The prognosis of patients with para-aortic lymph node metastasis is poor in pancreatic ductal adenocarcinoma. However, postoperative adjuvant chemotherapy may improve survival.
本研究旨在阐明胰腺导管腺癌中腹主动脉旁淋巴结转移的预后影响。
回顾性分析 103 例接受胰腺切除术加区域性和腹主动脉旁淋巴结清扫术的胰腺导管腺癌患者的病历。比较有腹主动脉旁淋巴结转移和无腹主动脉旁淋巴结转移患者的临床病理因素和生存情况。
肿瘤大小(p=0.045)、胰外神经丛侵犯(p=0.043)、UICC pT 分期(p=0.026)和手术切缘状态(p=0.002)与腹主动脉旁淋巴结转移显著相关。术后辅助化疗(p<0.001)和无胰外神经丛侵犯(p=0.041)与生存时间延长独立相关,但多因素分析显示腹主动脉旁淋巴结转移与生存时间无显著相关性(p=0.078)。有腹主动脉旁淋巴结转移和无腹主动脉旁淋巴结转移患者的 2 年和 5 年生存率和中位生存时间分别为 12%、0%、12.4 个月和 49%、23%、14.5 个月,两组生存情况差异有统计学意义(log-rank 检验,p<0.001)。术后辅助化疗显著改善了有腹主动脉旁淋巴结转移患者的生存情况(p=0.025)。
胰腺导管腺癌患者有腹主动脉旁淋巴结转移预后较差。然而,术后辅助化疗可能改善生存。